143 related articles for article (PubMed ID: 10051053)
1. Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients.
Kaplan B; Meier-Kriesche HU; Napoli KL; Kahan BD
Ther Drug Monit; 1999 Feb; 21(1):44-9. PubMed ID: 10051053
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients.
Seikku P; Hoppu K; Jalanko H; Holmberg C
Pediatr Transplant; 2003 Apr; 7(2):102-10. PubMed ID: 12654050
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
[TBL] [Abstract][Full Text] [Related]
4. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
[TBL] [Abstract][Full Text] [Related]
5. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
[TBL] [Abstract][Full Text] [Related]
7. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
Zhu L; Ding T; Wang XX; Lin ZB; Chen G
Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
[TBL] [Abstract][Full Text] [Related]
9. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS
Transplant Proc; 2006 Sep; 38(7):2032-4. PubMed ID: 16979990
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients.
Wang HF; Qiu F; Wu X; Fang J; Crownover P; Korth-Bradley J; Schulman S
Clin Pharmacol Drug Dev; 2014 May; 3(3):235-41. PubMed ID: 27128614
[TBL] [Abstract][Full Text] [Related]
11. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.
Chueh SC; Kahan BD
Transplantation; 2003 Jul; 76(2):375-82. PubMed ID: 12883196
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schädeli F; Marti HP; Frey FJ; Uehlinger DE
Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
[TBL] [Abstract][Full Text] [Related]
14. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
Baboolal K
Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
[TBL] [Abstract][Full Text] [Related]
15. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats.
Stepkowski SM; Napoli KL; Wang ME; Qu X; Chou TC; Kahan BD
Transplantation; 1996 Oct; 62(7):986-94. PubMed ID: 8878394
[TBL] [Abstract][Full Text] [Related]
16. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.
Kaplan B; Meier-Kriesche HU; Napoli KL; Kahan BD
Clin Pharmacol Ther; 1998 Jan; 63(1):48-53. PubMed ID: 9465841
[TBL] [Abstract][Full Text] [Related]
17. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients.
Brattström C; Säwe J; Tydén G; Herlenius G; Claesson K; Zimmerman J; Groth CG
Ther Drug Monit; 1997 Aug; 19(4):397-406. PubMed ID: 9263380
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.
Schachter AD; Benfield MR; Wyatt RJ; Grimm PC; Fennell RS; Herrin JT; Lirenman DS; McDonald RA; Munoz-Arizpe R; Harmon WE
Pediatr Transplant; 2006 Dec; 10(8):914-9. PubMed ID: 17096757
[TBL] [Abstract][Full Text] [Related]
19. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.
Le Meur Y; Djebli N; Szelag JC; Hoizey G; Toupance O; Rérolle JP; Marquet P
Clin Pharmacol Ther; 2006 Jul; 80(1):51-60. PubMed ID: 16815317
[TBL] [Abstract][Full Text] [Related]
20. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
